ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
But JNJ-75276617 still has much to prove.